Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 8 | 2017 | 64 | 1.740 |
Why?
|
| Pancreatic Neoplasms | 6 | 2020 | 140 | 1.640 |
Why?
|
| Postoperative Complications | 8 | 2020 | 779 | 1.510 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2018 | 33 | 1.190 |
Why?
|
| Bile Duct Neoplasms | 4 | 2015 | 36 | 1.120 |
Why?
|
| Pancreaticoduodenectomy | 4 | 2020 | 23 | 0.990 |
Why?
|
| Retrospective Studies | 21 | 2020 | 3488 | 0.900 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2014 | 21 | 0.880 |
Why?
|
| Pancreatectomy | 5 | 2014 | 32 | 0.850 |
Why?
|
| Aged | 26 | 2020 | 10288 | 0.800 |
Why?
|
| Liver Neoplasms | 4 | 2017 | 159 | 0.780 |
Why?
|
| Cause of Death | 2 | 2014 | 238 | 0.770 |
Why?
|
| Female | 35 | 2020 | 19859 | 0.770 |
Why?
|
| Middle Aged | 27 | 2020 | 11824 | 0.750 |
Why?
|
| Male | 29 | 2020 | 19091 | 0.680 |
Why?
|
| Neoplasm Staging | 9 | 2016 | 456 | 0.680 |
Why?
|
| Biliary Dyskinesia | 1 | 2019 | 3 | 0.670 |
Why?
|
| Humans | 38 | 2020 | 31836 | 0.660 |
Why?
|
| Risk Assessment | 9 | 2018 | 1431 | 0.650 |
Why?
|
| Adenocarcinoma | 4 | 2019 | 311 | 0.640 |
Why?
|
| Gallbladder Neoplasms | 2 | 2015 | 36 | 0.630 |
Why?
|
| Survivors | 2 | 2016 | 159 | 0.620 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2013 | 9 | 0.620 |
Why?
|
| Cholangiocarcinoma | 3 | 2013 | 14 | 0.620 |
Why?
|
| Survival Rate | 8 | 2017 | 884 | 0.610 |
Why?
|
| Cohort Studies | 8 | 2016 | 1824 | 0.600 |
Why?
|
| Breast Neoplasms | 4 | 2018 | 760 | 0.600 |
Why?
|
| Computer Systems | 1 | 2017 | 13 | 0.590 |
Why?
|
| Preoperative Care | 1 | 2018 | 115 | 0.590 |
Why?
|
| Vascular Surgical Procedures | 2 | 2015 | 90 | 0.590 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 21 | 0.590 |
Why?
|
| Abdomen | 1 | 2017 | 44 | 0.580 |
Why?
|
| Frail Elderly | 1 | 2017 | 68 | 0.560 |
Why?
|
| Pancreatitis, Chronic | 1 | 2016 | 9 | 0.550 |
Why?
|
| Hospital Mortality | 2 | 2016 | 190 | 0.540 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2016 | 33 | 0.540 |
Why?
|
| Patient Care | 1 | 2016 | 31 | 0.530 |
Why?
|
| Neoplasm Invasiveness | 5 | 2014 | 194 | 0.520 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2015 | 8 | 0.520 |
Why?
|
| Exercise Therapy | 1 | 2018 | 268 | 0.520 |
Why?
|
| Bile Ducts | 1 | 2015 | 21 | 0.520 |
Why?
|
| Blood Vessels | 1 | 2015 | 49 | 0.510 |
Why?
|
| SEER Program | 5 | 2016 | 35 | 0.490 |
Why?
|
| Ileal Diseases | 1 | 2014 | 3 | 0.490 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 2271 | 0.490 |
Why?
|
| Cholelithiasis | 1 | 2014 | 11 | 0.490 |
Why?
|
| Hernia, Abdominal | 1 | 2014 | 10 | 0.490 |
Why?
|
| Intestinal Obstruction | 1 | 2014 | 12 | 0.480 |
Why?
|
| Peritoneal Neoplasms | 3 | 2014 | 262 | 0.470 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2013 | 7 | 0.460 |
Why?
|
| Ampulla of Vater | 1 | 2013 | 7 | 0.460 |
Why?
|
| Duodenal Neoplasms | 1 | 2013 | 6 | 0.460 |
Why?
|
| Carcinoid Tumor | 1 | 2013 | 14 | 0.460 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 13 | 0.450 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 216 | 0.450 |
Why?
|
| Carcinoma | 1 | 2014 | 92 | 0.430 |
Why?
|
| Hospitalization | 1 | 2016 | 463 | 0.430 |
Why?
|
| Pancreatitis | 1 | 2013 | 22 | 0.430 |
Why?
|
| Treatment Outcome | 11 | 2017 | 3294 | 0.430 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 49 | 0.420 |
Why?
|
| Depression | 1 | 2016 | 442 | 0.420 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 686 | 0.410 |
Why?
|
| Length of Stay | 4 | 2017 | 315 | 0.410 |
Why?
|
| United States | 7 | 2018 | 3925 | 0.400 |
Why?
|
| Fundoplication | 1 | 2011 | 8 | 0.390 |
Why?
|
| Gastroparesis | 1 | 2011 | 11 | 0.390 |
Why?
|
| Gastroesophageal Reflux | 1 | 2011 | 25 | 0.390 |
Why?
|
| Gastrectomy | 1 | 2011 | 67 | 0.380 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 90 | 0.380 |
Why?
|
| Prognosis | 8 | 2020 | 1498 | 0.380 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 37 | 0.370 |
Why?
|
| Breast Diseases | 1 | 2010 | 4 | 0.370 |
Why?
|
| Scleroderma, Localized | 1 | 2010 | 5 | 0.370 |
Why?
|
| Patient Transfer | 1 | 2011 | 44 | 0.360 |
Why?
|
| Erythema | 1 | 2010 | 27 | 0.360 |
Why?
|
| Patient Care Planning | 1 | 2011 | 59 | 0.350 |
Why?
|
| African Americans | 1 | 2016 | 1428 | 0.340 |
Why?
|
| Survival Analysis | 5 | 2014 | 487 | 0.340 |
Why?
|
| Time Factors | 5 | 2015 | 2146 | 0.300 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 3988 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 461 | 0.300 |
Why?
|
| Hyperthermia, Induced | 3 | 2014 | 246 | 0.290 |
Why?
|
| Pancreatic Fistula | 2 | 2020 | 5 | 0.290 |
Why?
|
| Internship and Residency | 1 | 2011 | 306 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2014 | 369 | 0.280 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 257 | 0.250 |
Why?
|
| Logistic Models | 3 | 2017 | 777 | 0.220 |
Why?
|
| Risk Factors | 5 | 2018 | 3851 | 0.220 |
Why?
|
| Minnesota | 2 | 2014 | 21 | 0.220 |
Why?
|
| Adult | 10 | 2018 | 9327 | 0.210 |
Why?
|
| Vena Cava, Inferior | 2 | 2012 | 32 | 0.210 |
Why?
|
| Odds Ratio | 2 | 2015 | 470 | 0.210 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 756 | 0.210 |
Why?
|
| Age Factors | 2 | 2016 | 1187 | 0.200 |
Why?
|
| Academic Medical Centers | 2 | 2014 | 156 | 0.200 |
Why?
|
| Recurrence | 2 | 2013 | 262 | 0.200 |
Why?
|
| Lymphatic Metastasis | 4 | 2016 | 170 | 0.180 |
Why?
|
| Mastectomy | 2 | 2018 | 65 | 0.170 |
Why?
|
| Omentum | 2 | 2017 | 26 | 0.170 |
Why?
|
| Surgical Wound Infection | 2 | 2018 | 85 | 0.170 |
Why?
|
| Feasibility Studies | 2 | 2017 | 291 | 0.160 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 19 | 0.160 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 3 | 2014 | 158 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2018 | 349 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 912 | 0.150 |
Why?
|
| Hospital Information Systems | 1 | 2017 | 3 | 0.150 |
Why?
|
| Computer Communication Networks | 1 | 2017 | 5 | 0.150 |
Why?
|
| Tumor Burden | 2 | 2016 | 60 | 0.150 |
Why?
|
| Neoplasms | 2 | 2014 | 692 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 24 | 0.150 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 4 | 0.140 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2017 | 20 | 0.140 |
Why?
|
| Laparotomy | 1 | 2017 | 30 | 0.140 |
Why?
|
| Incidence | 2 | 2017 | 1192 | 0.140 |
Why?
|
| Cells, Immobilized | 1 | 2017 | 23 | 0.140 |
Why?
|
| Morbidity | 1 | 2017 | 99 | 0.140 |
Why?
|
| Mastectomy, Segmental | 1 | 2016 | 27 | 0.140 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2017 | 36 | 0.140 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2017 | 47 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2017 | 54 | 0.140 |
Why?
|
| Analgesia, Epidural | 1 | 2017 | 51 | 0.140 |
Why?
|
| Islets of Langerhans | 1 | 2017 | 76 | 0.140 |
Why?
|
| Health Surveys | 1 | 2016 | 196 | 0.140 |
Why?
|
| Walking | 1 | 2017 | 208 | 0.130 |
Why?
|
| Mammaplasty | 2 | 2018 | 28 | 0.130 |
Why?
|
| Safety | 1 | 2016 | 78 | 0.130 |
Why?
|
| Anastomosis, Surgical | 1 | 2015 | 59 | 0.130 |
Why?
|
| Shock, Septic | 1 | 2015 | 26 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2015 | 47 | 0.130 |
Why?
|
| Health Care Surveys | 1 | 2016 | 186 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 178 | 0.120 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 390 | 0.120 |
Why?
|
| Abdominal Cavity | 1 | 2014 | 6 | 0.120 |
Why?
|
| Medicare | 1 | 2016 | 206 | 0.120 |
Why?
|
| Health Status | 1 | 2017 | 397 | 0.120 |
Why?
|
| Abdominal Neoplasms | 1 | 2014 | 15 | 0.120 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 564 | 0.120 |
Why?
|
| Pancreas | 1 | 2015 | 103 | 0.120 |
Why?
|
| Young Adult | 3 | 2017 | 2603 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 131 | 0.110 |
Why?
|
| Reference Values | 1 | 2014 | 247 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 319 | 0.110 |
Why?
|
| Laparoscopy | 2 | 2017 | 171 | 0.110 |
Why?
|
| Giant Cells | 1 | 2012 | 5 | 0.110 |
Why?
|
| Portal Vein | 1 | 2012 | 28 | 0.110 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2012 | 5 | 0.100 |
Why?
|
| Sarcoma, Synovial | 1 | 2012 | 7 | 0.100 |
Why?
|
| Vascular Neoplasms | 1 | 2012 | 13 | 0.100 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2012 | 57 | 0.100 |
Why?
|
| Pericardium | 1 | 2012 | 52 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2012 | 61 | 0.100 |
Why?
|
| Sex Factors | 1 | 2014 | 662 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2014 | 895 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 874 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 221 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2011 | 162 | 0.100 |
Why?
|
| Mammography | 1 | 2011 | 42 | 0.100 |
Why?
|
| Total Quality Management | 1 | 2011 | 18 | 0.090 |
Why?
|
| Efficiency, Organizational | 1 | 2011 | 19 | 0.090 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 31 | 0.090 |
Why?
|
| Quality of Life | 1 | 2016 | 924 | 0.090 |
Why?
|
| Medical Errors | 1 | 2011 | 37 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 48 | 0.090 |
Why?
|
| Peritoneal Lavage | 1 | 2010 | 2 | 0.090 |
Why?
|
| Cytodiagnosis | 1 | 2010 | 16 | 0.090 |
Why?
|
| Stents | 1 | 2012 | 178 | 0.090 |
Why?
|
| Linear Models | 1 | 2011 | 449 | 0.090 |
Why?
|
| Reoperation | 1 | 2011 | 226 | 0.090 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2012 | 199 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2011 | 184 | 0.090 |
Why?
|
| Obesity | 1 | 2018 | 1158 | 0.090 |
Why?
|
| General Surgery | 1 | 2011 | 80 | 0.090 |
Why?
|
| Probability | 1 | 2010 | 158 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 95 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2011 | 129 | 0.090 |
Why?
|
| Patient Selection | 1 | 2011 | 276 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 1323 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 531 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 518 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 899 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2017 | 2277 | 0.060 |
Why?
|
| Adolescent | 3 | 2018 | 3511 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 192 | 0.060 |
Why?
|
| Lymphopenia | 1 | 2017 | 12 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2017 | 14 | 0.040 |
Why?
|
| Leucovorin | 1 | 2017 | 25 | 0.040 |
Why?
|
| Neutropenia | 1 | 2017 | 30 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 12 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 20 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 31 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 61 | 0.040 |
Why?
|
| Sulfides | 1 | 2017 | 27 | 0.040 |
Why?
|
| Caprylates | 1 | 2017 | 28 | 0.040 |
Why?
|
| Camptothecin | 1 | 2017 | 52 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 47 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2017 | 45 | 0.040 |
Why?
|
| Capsules | 1 | 2017 | 15 | 0.040 |
Why?
|
| Fluid Therapy | 1 | 2017 | 25 | 0.040 |
Why?
|
| Anemia | 1 | 2017 | 59 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2017 | 82 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2017 | 37 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2017 | 84 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2017 | 73 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 63 | 0.030 |
Why?
|
| Alginates | 1 | 2017 | 53 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 242 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 286 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 144 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 158 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 351 | 0.030 |
Why?
|
| Graft Survival | 1 | 2017 | 314 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2015 | 15 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 566 | 0.030 |
Why?
|
| Insulin | 1 | 2017 | 366 | 0.030 |
Why?
|
| Colectomy | 1 | 2014 | 23 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 916 | 0.030 |
Why?
|
| Mitomycin | 1 | 2014 | 52 | 0.030 |
Why?
|
| Diaphragm | 1 | 2014 | 40 | 0.030 |
Why?
|
| Cisplatin | 1 | 2014 | 77 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 149 | 0.030 |
Why?
|
| Hepatic Veins | 1 | 2012 | 4 | 0.030 |
Why?
|
| Rats | 1 | 2017 | 1586 | 0.030 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2012 | 4 | 0.030 |
Why?
|
| Ablation Techniques | 1 | 2012 | 26 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2012 | 70 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2012 | 43 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 461 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2012 | 78 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2012 | 81 | 0.020 |
Why?
|
| Heart Atria | 1 | 2012 | 69 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 87 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 97 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2476 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 589 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 607 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7450 | 0.020 |
Why?
|